Ticker brief
VRDN VIRIDIAN THERAPEUTICS INC
Consumer, Non-cyclical · Biotechnology
last close
$19.40
1 day
+5.0%
14 days
+16.7%
mkt cap
$2.1B
signals 14d
22
authors 14d
17
Sentiment — last 14 days
daily mean sentiment, 2026-06-19 → 2026-06-30 · now +0.50 (−1 bearish … +1 bullish)
Who spoke17
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Quantumup1 | C | -1.95 | 3 | +0.55 |
| @BPharmCatalyst | C | · | 2 | +0.00 |
| @OpenOutcrier | C | · | 2 | +0.40 |
| @BiopharmIQ | B | · | 2 | +0.47 |
| @adamfeuerstein | A | +1.05 | 1 | +0.50 |
| @PolycarpFX | B | +0.45 | 1 | +0.45 |
| @AlertsAndNews | C | +1.52 | 1 | +0.50 |
| @SeegerErik | C | -1.01 | 1 | +0.15 |
| @BenzingaSpain | C | -0.88 | 1 | +0.00 |
| @MartyChargin | C | -0.72 | 1 | +0.50 |
| @ABBONews | C | · | 1 | +0.50 |
| @TENETTRADEGROUP | C | -0.70 | 1 | +0.00 |
| @ScalpIdeas | C | · | 1 | +0.40 |
| @fwpharma | B | +0.22 | 1 | +0.50 |
| @financespotnews | C | -0.87 | 1 | +0.60 |
| @USAnt_IDEA | C | -0.65 | 1 | +0.50 |
| @FiercePharma | B | +1.39 | 1 | +0.50 |
Recent signals22of 22 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-06-30 | @FiercePharma | +0.50 | Viridian secured FDA approval for Lumvoa, creating competition for Amgen Tepezza. | +5.6% | tweet ↗ |
| 2026-06-29 | @USAnt_IDEA | +0.50 | Korean biotech pipeline roundup cites FDA approvals, trial starts, and results. | +3.2% | tweet ↗ |
| 2026-06-29 | @BiopharmIQ | +0.50 | FDA recap: IONS and VRDN approvals; LNTH CRL due to manufacturing facility issues. | +3.2% | tweet ↗ |
| 2026-06-29 | @OpenOutcrier | +0.30 | Recaps positive and negative third-party comments on multiple tickers. | +3.2% | tweet ↗ |
| 2026-06-29 | @BiopharmIQ | +0.45 | Biotech stock news list with percent moves and catalysts at open. | +3.2% | tweet ↗ |
| 2026-06-29 | @Quantumup1 | +0.55 | William Blair and Wedbush reiterate bullish VRDN views; Wedbush raises PT to $43 from $32. | +3.2% | tweet ↗ |
| 2026-06-29 | @financespotnews | +0.60 | FDA approved Viridian drug for thyroid eye disease, creating commercial milestone. | +3.2% | tweet ↗ |
| 2026-06-29 | @fwpharma | +0.50 | Viridian thyroid eye disease drug won FDA approval, competing with Amgen Tepezza. | +3.2% | tweet ↗ |
| 2026-06-29 | @ScalpIdeas | +0.40 | Wells Fargo upgrades VRDN to Overweight from Equalweight. | +3.2% | tweet ↗ |
| 2026-06-29 | @OpenOutcrier | +0.50 | Viridian won its first FDA approval. | +3.2% | tweet ↗ |
| 2026-06-29 | @Quantumup1 | +0.55 | UBS reiterates VRDN Buy $50 after Lumvoa approval and outlines TAM and launch expectations. | +3.2% | tweet ↗ |
| 2026-06-29 | @TENETTRADEGROUP | +0.00 | Premarket movers ticker list without explicit stance. | +3.2% | tweet ↗ |
| 2026-06-29 | @Quantumup1 | +0.55 | Citizens reiterates VRDN Market Outperform $35 after FDA approval of Lumvoa. | +3.2% | tweet ↗ |
| 2026-06-29 | @ABBONews | +0.50 | FDA approved Lumvoa ahead of PDUFA; Citizens reiterated rating and $35 PT. | +3.2% | tweet ↗ |
| 2026-06-29 | @MartyChargin | +0.50 | Viridian announces U.S. FDA approval and launch of Lumvoa for thyroid eye disease. | +3.2% | tweet ↗ |
| 2026-06-29 | @BenzingaSpain | +0.00 | Lists five US stocks that could attract investor attention Monday premarket. | +3.2% | tweet ↗ |
| 2026-06-29 | @SeegerErik | +0.15 | Broad premarket ticker list with repeated bullish setup narrative. | +3.2% | tweet ↗ |
| 2026-06-28 | @AlertsAndNews | +0.50 | Viridian received U.S. FDA approval and launched Lumvoa for thyroid eye disease. | +8.4% | tweet ↗ |
| 2026-06-26 | @PolycarpFX | +0.45 | Suggests long-term involvement in VRDN and positive view of biotech name. | +8.4% | tweet ↗ |
| 2026-06-26 | @adamfeuerstein | +0.50 | Reports VRDN approval. | +8.4% | tweet ↗ |
| 2026-06-19 | @BPharmCatalyst | +0.00 | Biotech watchlist calendar names tickers but gives no stance. | +16.7% | tweet ↗ |
| 2026-06-19 | @BPharmCatalyst | +0.00 | Weekly biotech watchlist lists tickers without specific stance. | +16.7% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.